Rydex Health Care H RYHAX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 37.16  /  +0.38 %
  • Total Assets 26.8 Mil
  • Adj. Expense Ratio
    1.650%
  • Expense Ratio 1.650%
  • Distribution Fee Level High
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield 0.00
  • Turnover 116%

USD | NAV as of Oct 05, 2024 | 1-Day Return as of Oct 05, 2024, 12:57 AM GMT+0

Morningstar’s Analysis RYHAX

Will RYHAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A lowering of its Process Pillar rating is the primary driver of Rydex Health Care H's downgrade to a Morningstar Medalist Rating of Negative from Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYHAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 26.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

4.27 1.3 Mil
Healthcare

UnitedHealth Group Inc

3.67 1.1 Mil
Healthcare

Johnson & Johnson

3.05 955,851
Healthcare

AbbVie Inc

2.89 903,222
Healthcare

Merck & Co Inc

2.38 743,866
Healthcare

Thermo Fisher Scientific Inc

2.28 713,481
Healthcare

Abbott Laboratories

2.10 655,720
Healthcare

Intuitive Surgical Inc

2.04 636,971
Healthcare

Amgen Inc

2.03 636,614
Healthcare

Danaher Corp

2.02 630,724
Healthcare

Sponsor Center